7AC.F ACARIX AB
- Market cap
- EUR 9.92M
- P/E
- -
- P/B
- 2.49x
- ROE
- -83.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 7AC.F undervalued?
Graham numberThe Graham number of ACARIX AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ACARIX AB fundamental analysis
No fundamental analysis for ACARIX AB yet.
ACARIX AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ACARIX AB
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to support clinical decision making at the point of care. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is …
Full company profileACARIX AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ACARIX AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 3.76M | 5.82M | 6.24M | 6.20M | 7.36M | 9.46M |
| Gross Profit | 2.82M | 4.62M | 5.30M | 5.60M | 6.24M | 7.81M |
| Operating Income | -51.7M | -76.5M | -77.6M | -66.4M | -48.0M | -35.5M |
| EBITDA | - | -73.8M | -74.6M | -62.8M | -44.6M | -32.0M |
| Net Income | -51.7M | -77.0M | -77.8M | -66.2M | -48.1M | -36.5M |
| EPS | -0.17 | -0.25 | -0.11 | -0.06 | -0.04 | -0.03 |
| Balance Sheet | ||||||
| Total Assets | 119M | 69.5M | 62.9M | 80.8M | 48.3M | 47.7M |
| Total Liabilities | 18.1M | 17.7M | 11.0M | 5.06M | 10.2M | 3.96M |
| Shareholders' Equity | 101M | 51.8M | 51.9M | 75.7M | 38.2M | 43.8M |
| Cash & Short-term Investments | 15.8M | 6.62M | 30.6M | 54.0M | 18.3M | 28.9M |
| Cash Flow | ||||||
| Operating Cash Flow | -48.0M | -74.9M | -81.4M | -63.3M | -37.3M | -21.4M |
| Capital Expenditure | 43.0K | 151K | 0.00 | 920K | 757K | 678K |
| Free Cash Flow | -48.1M | -75.0M | -81.4M | -64.2M | -38.0M | -22.1M |
| Ratios | ||||||
| ROE | -51.5% | -148.5% | -150.0% | -87.4% | -126.0% | -83.4% |
| ROA | -43.6% | -110.8% | -123.8% | -82.0% | -99.5% | -76.5% |
| Net Profit Margin | -1,375.8% | -1,322.3% | -1,247.2% | -1,067.2% | -653.3% | -385.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ACARIX AB dividends
ACARIX AB has not paid dividends in the last 5 fiscal years.
Who owns ACARIX AB
- Insiders 10.87%
- Institutions 7.48%
- Public & others 81.66%
- Shares outstanding 1.24B
- Free float 1.10B
ACARIX AB company profile
- Company name
- ACARIX AB
- Ticker
- 7AC.F
- ISIN
- SE0009268717
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 8
- Fiscal year end
- December
- Address
- Regus MalmOe, Malmö, Sweden, 215 32
- Website
- acarix.com
About ACARIX AB
Acarix AB (publ), a medical device company, develops solutions for rapid AI-based coronary artery disease rule-out. The company offers CADScor System, a point-of-care diagnostic aid that uses sensitive acoustics and advanced computational processing to support clinical decision making at the point of care. It sells its products in the Nordic countries, the United Kingdom, Germany, Switzerland, Austria, Mauritius, and the United States. The company was founded in 2009 and is headquartered in Malmö, Sweden.
ACARIX AB management
6- Mr. Aamir MahmoodPresident & CEO · born 1976
- Mr. Christian LindholmCFO & Executive VP · born 1964
- Ms. Carma ConnelyHead of Operations & Customer Excellence · born 1975
- Mr. Andrew TurkDirector of Sales · born 1978
- Dr. George Chrysant M.D.Chief Medical Advisor · born 1970
- Mr. Jeffrey RuddHead of US Finance · born 1977